Baidu
map

再生障碍性贫血诊断与治疗中国专家共识(2017版)解读

2017-11-30 临床血液学杂志.2017,30(11):821-825.

再生障碍性贫血(AA)的特点为全血细胞减少和骨髓造血功能衰竭,重型患者起病急,病情进展迅速,如不能得到及时有效治疗,患者常死于严重的出血或感染。经过多年的临床探索,其诊断和治疗水平已经明显提高。自2010年我国制定第1版AA诊治专家共识至今,已历时6年,关于该疾病的诊疗,已经发生了一些变化。为进一步更好地指导我国临床医生对AA的诊疗工作。2016年中华医学会血液学分会红细胞疾病(贫血)学组对原版专

中文标题:

再生障碍性贫血诊断与治疗中国专家共识(2017版)解读

发布机构:

发布日期:

2017-11-30

简要介绍:

再生障碍性贫血(AA)的特点为全血细胞减少和骨髓造血功能衰竭,重型患者起病急,病情进展迅速,如不能得到及时有效治疗,患者常死于严重的出血或感染。经过多年的临床探索,其诊断和治疗水平已经明显提高。自2010年我国制定第1版AA诊治专家共识至今,已历时6年,关于该疾病的诊疗,已经发生了一些变化。为进一步更好地指导我国临床医生对AA的诊疗工作。2016年中华医学会血液学分会红细胞疾病(贫血)学组对原版专家共识进行了修订,现对修订版共识做一解读,以供参考。

作者: 天津医科大学总医院血液内科 付蓉 刘春燕

 

拓展指南:贫血相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=再生障碍性贫血诊断与治疗中国专家共识(2017版)解读)] GetToolGuiderByIdResponse(projectId=1, id=447341c001518e4c, title=再生障碍性贫血诊断与治疗中国专家共识(2017版)解读, enTitle=, guiderFrom=临床血液学杂志.2017,30(11):821-825., authorId=null, author=, summary=再生障碍性贫血(AA)的特点为全血细胞减少和骨髓造血功能衰竭,重型患者起病急,病情进展迅速,如不能得到及时有效治疗,患者常死于严重的出血或感染。经过多年的临床探索,其诊断和治疗水平已经明显提高。自2010年我国制定第1版AA诊治专家共识至今,已历时6年,关于该疾病的诊疗,已经发生了一些变化。为进一步更好地指导我国临床医生对AA的诊疗工作。2016年中华医学会血液学分会红细胞疾病(贫血)学组对原版专, cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Thu Nov 30 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>再生障碍性贫血(AA)的特点为全血细胞减少和骨髓造血功能衰竭,重型患者起病急,病情进展迅速,如不能得到及时有效治疗,患者常死于严重的出血或感染。经过多年的临床探索,其诊断和治疗水平已经明显提高。自2010年我国制定第1版AA诊治专家共识至今,已历时6年,关于该疾病的诊疗,已经发生了一些变化。为进一步更好地指导我国临床医生对AA的诊疗工作。2016年中华医学会血液学分会红细胞疾病(贫血)学组对原版专家共识进行了修订,现对修订版共识做一解读,以供参考。 </P>作者: 天津医科大学总医院血液内科 付蓉 刘春燕 <P> </P>拓展指南:<strong>与<font color=red>贫血</font>相关指南:</strong><br><ul><li><a href="//m.sandwebs.com/guideline/show_article.do?id=2fd9a1c001a811b5" title="2017 BCSH指南:药物引起的免疫以及二次免疫溶血性贫血的管理" target=_blank>2017 BCSH指南:药物引起的免疫以及二次免疫溶血性贫血的管理</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=d31f71c001ae01d0" title="自身免疫性溶血性贫血诊断与治疗中国专家共识(2017年版)" target=_blank>自身免疫性溶血性贫血诊断与治疗中国专家共识(2017年版)</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=d04561c001a62435" title="NCCN临床实践指南:癌症和化疗诱导的贫血(2018.V1)" target=_blank>NCCN临床实践指南:癌症和化疗诱导的贫血(2018.V1)</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=bb3bb1c001a580b5" title="2017 RA临床实践指南:慢性肾病贫血" target=_blank>2017 RA临床实践指南:慢性肾病贫血</a></li> <li><a href="//m.sandwebs.com/guideline/show_article.do?id=d69b91c001a463b8" title="2017 EHA建议:脾切除术治疗遗传性溶血性贫血" target=_blank>2017 EHA建议:脾切除术治疗遗传性溶血性贫血</a></li> 更多信息请点击:<a href="//m.sandwebs.com/guideline/list.do?q=%E8%B4%AB%E8%A1%80" target=_blank>有关贫血更多指南</a></ul>, tagList=[TagDto(tagId=11859, tagName=再生障碍性贫血)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8396, appHits=777, showAppHits=9, pcHits=5054, showPcHits=4156, likes=136, shares=30, comments=3, approvalStatus=1, publishedTime=Sun Nov 12 20:06:41 CST 2017, publishedTimeString=2017-11-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Nov 12 20:06:41 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 19:34:44 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=再生障碍性贫血诊断与治疗中国专家共识(2017版)解读)])
再生障碍性贫血诊断与治疗中国专家共识(2017版)解读
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1209019, encodeId=afa41209019cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4966463174, createdName=ms4000001836182945, createdTime=Wed Apr 06 17:14:46 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953567, encodeId=d44d95356e80, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f15d3890604, createdName=1381d648m98暂无昵称, createdTime=Sat Apr 03 17:03:38 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282278, encodeId=54232822e8be, content=又学习了.很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2b82259320, createdName=1217e9d9m52暂无昵称, createdTime=Fri Jan 26 21:00:45 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2022-04-06 ms4000001836182945

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1209019, encodeId=afa41209019cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4966463174, createdName=ms4000001836182945, createdTime=Wed Apr 06 17:14:46 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953567, encodeId=d44d95356e80, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f15d3890604, createdName=1381d648m98暂无昵称, createdTime=Sat Apr 03 17:03:38 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282278, encodeId=54232822e8be, content=又学习了.很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2b82259320, createdName=1217e9d9m52暂无昵称, createdTime=Fri Jan 26 21:00:45 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2021-04-03 1381d648m98暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1209019, encodeId=afa41209019cf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4966463174, createdName=ms4000001836182945, createdTime=Wed Apr 06 17:14:46 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953567, encodeId=d44d95356e80, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f15d3890604, createdName=1381d648m98暂无昵称, createdTime=Sat Apr 03 17:03:38 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282278, encodeId=54232822e8be, content=又学习了.很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2b82259320, createdName=1217e9d9m52暂无昵称, createdTime=Fri Jan 26 21:00:45 CST 2018, time=2018-01-26, status=1, ipAttribution=)]
    2018-01-26 1217e9d9m52暂无昵称

    又学习了.很有收获

    0

Baidu
map
Baidu
map
Baidu
map